Brivaracetam use in clinical practice: a Delphi consensus on its role as first add-on therapy in focal epilepsy and beyond
Neurological Sciences · 2024-09 · 45 (9) · 4519-4527
DOI: 10.1007/s10072-024-07485-w ↗Kurz gefasst
Delphi-Studie in der Zeitschrift Neurological Sciences, online erschienen am 01.04.2024. Verfasst von Simona Lattanzi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental and Clinical Medicine, Neurological Clinic, Marche Polytechnic University, Via Conca 71, 60020, Ancona, Italy. alfierelatt…. Hauptthemen laut MEDLINE: Pyrrolidinones, Anticonvulsants, Epilepsies, Partial, Delphi Technique. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Università Politecnica delle Marche.
Abstract (Originalsprache)
Background
Antiseizure medications remain the cornerstone of treatment for epilepsy, although a proportion of individuals with the condition will continue to experience seizures despite appropriate therapy. Treatment choices for epilepsy are based on variables related to both the individual patient and the available medications. Brivaracetam is a third-generation agent antiseizure medication.
Methods
We carried out a Delphi consensus exercise to define the role of brivaracetam in clinical practice and to provide guidance about its use as first add-on ASM and in selected clinical scenarios. A total of 15 consensus statements were drafted by an expert panel following review of the literature and all were approved in the first round of voting by panelists. The consensus indicated different clinical scenarios for which brivaracetam can be a good candidate for treatment, including first add-on use.
Results
Overall, brivaracetam was considered to have many advantageous characteristics that render it a suitable option for patients with focal epilepsy, including a fast onset of action, favorable pharmacokinetic profile with few drug-drug interactions, broad-spectrum activity, and being well tolerated across a range of doses. Brivaracetam is also associated with sustained clinical response and good tolerability in the long term.
Conclusions
These characteristics also make it suitable as an early add-on for the elderly and for patients with post-stroke epilepsy or status epilepticus as highlighted by the present Delphi consensus.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Experimental and Clinical Medicine, Neurological Clinic, Marche Polytechnic University, Via Conca 71, 60020, Ancona, Italy. alfierelattanzisimona@gmail.com.
- Epilepsy Center, Child Neurology Unit, ASST Santi Paolo Carlo, Milan, Italy.
- IRCCS Neuromed, Pozzilli, Italy.
- Department of Medical and Surgical Sciences, Magna Græcia University of Catanzaro, Catanzaro, Italy.
- Neurophysiopathology and Movement Disorders Clinic, University of Messina, Messina, Italy.
- DiBraiN, University Hospital of Bari "A. Moro", Bari, Italy.
Förderung
- Università Politecnica delle Marche
Zitieren
APA
Lattanzi, S., Chiesa, V., Di Gennaro, G., Ferlazzo, E., Labate, A., La Neve, A., Meletti, S., Di Bonaventura, C., & Consensus Collaborators Group (2024). Brivaracetam use in clinical practice: a Delphi consensus on its role as first add-on therapy in focal epilepsy and beyond. Neurological Sciences, 45(9), 4519-4527. https://doi.org/10.1007/s10072-024-07485-w
Vancouver
Lattanzi S, Chiesa V, Di Gennaro G, Ferlazzo E, Labate A, La Neve A, et al. Brivaracetam use in clinical practice: a Delphi consensus on its role as first add-on therapy in focal epilepsy and beyond. Neurological Sciences. 2024;45(9):4519-4527. doi:10.1007/s10072-024-07485-w
BibTeX
@article{Lattanzi2024,
author = {Lattanzi, Simona and Chiesa, Valentina and Di Gennaro, Giancarlo and Ferlazzo, Edoardo and Labate, Angelo and La Neve, Angela and Meletti, Stefano and Di Bonaventura, Carlo and Consensus Collaborators Group, Consensus Collaborators Group},
title = {Brivaracetam use in clinical practice: a Delphi consensus on its role as first add-on therapy in focal epilepsy and beyond},
journal = {Neurological Sciences},
year = {2024},
volume = {45},
number = {9},
pages = {4519--4527},
doi = {10.1007/s10072-024-07485-w}
}
EUVIMED